Blueprint
Stock
Stock
Ticker: BPMC
BPMC
Price
Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Blueprint?
Blueprint's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -2.461. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Blueprint's stock?
Currently, 1 analysts cover Blueprint's stock, with a consensus target price of $132.00. Analyst ratings provide insights into the stock's expected performance.
What is Blueprint's revenue over the trailing twelve months?
Over the trailing twelve months, Blueprint reported a revenue of $562.12M.
What is the EBITDA for Blueprint?
Blueprint's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$158.37M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Blueprint?
Blueprint has a free cash flow of -$150.91M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Blueprint have, and what sector and industry does it belong to?
Blueprint employs approximately 649 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
Financials
- EPS (TTM)
- -2.461
- Revenue (TTM)
- $562.12M
- EBITDA (TTM)
- -$158.37M
- Free Cashflow (TTM)
- -$150.91M
Analyst Ratings
The price target is $132.00 and the stock is covered by 1 analysts.
Buy
0
Hold
0
Sell
1
Information
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
- Employees
- 649
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- BPMC
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet